This early-stage trial tests whether adding an experimental treatment (MB097) to a standard immunotherapy (pembrolizumab) is safe and shows signs of working in people with advanced melanoma that did not respond to prior anti-PD1 therapy. About 41 participants will receive the com…
Phase: PHASE1 • Sponsor: Microbiotica Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC